{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:30:38Z","timestamp":1770903038295,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1245\/s10434-025-18691-x","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T23:22:15Z","timestamp":1762730535000},"page":"2632-2641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy"],"prefix":"10.1245","volume":"33","author":[{"given":"Robin D.","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ju","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Wei D.","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica E.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruhiko","family":"Ikoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew H. G.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2485-2481","authenticated-orcid":false,"given":"Rebecca A.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"issue":"6","key":"18691_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, Silverstein MD, Mohr DN, Petterson TM, O\u2019Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809\u201315. https:\/\/doi.org\/10.1001\/archinte.160.6.809.","journal-title":"Arch Intern Med."},{"issue":"4","key":"18691_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458\u201364. https:\/\/doi.org\/10.1001\/archinte.166.4.458.","journal-title":"Arch Intern Med."},{"issue":"10","key":"18691_CR3","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/cncr.23062","volume":"110","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339\u201346. https:\/\/doi.org\/10.1002\/cncr.23062.","journal-title":"Cancer."},{"issue":"9","key":"18691_CR4","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1200\/JOP.2016.015818","volume":"12","author":"S Tsai","year":"2016","unstructured":"Tsai S, Erickson BA, Dua K, Ritch PS, Tolat P, Evans DB. Evolution of the management of resectable pancreatic cancer. J Oncol Pract. 2016;12(9):772\u20138. https:\/\/doi.org\/10.1200\/JOP.2016.015818.","journal-title":"J Oncol Pract."},{"issue":"5","key":"18691_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W, et al. Patterns, Timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267(5):936\u201345. https:\/\/doi.org\/10.1097\/SLA.0000000000002234.","journal-title":"Ann Surg."},{"issue":"6","key":"18691_CR6","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ejso.2008.12.006","volume":"35","author":"A Van den Broeck","year":"2009","unstructured":"Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2009;35(6):600\u20134. https:\/\/doi.org\/10.1016\/j.ejso.2008.12.006.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol."},{"issue":"2","key":"18691_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s002689900215","volume":"21","author":"C Sperti","year":"1997","unstructured":"Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21(2):195\u2013200. https:\/\/doi.org\/10.1007\/s002689900215.","journal-title":"World J Surg."},{"issue":"2","key":"18691_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMp030086","volume":"349","author":"RL Bick","year":"2003","unstructured":"Bick RL. Cancer-associated thrombosis. N Engl J Med. 2003;349(2):109\u201311. https:\/\/doi.org\/10.1056\/NEJMp030086.","journal-title":"N Engl J Med."},{"issue":"10","key":"18691_CR9","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902\u20137. https:\/\/doi.org\/10.1182\/blood-2007-10-116327.","journal-title":"Blood."},{"issue":"5","key":"18691_CR10","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1053\/j.gastro.2019.12.009","volume":"158","author":"C Frere","year":"2020","unstructured":"Frere C, Bournet B, Gourgou S, et al. Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes. Gastroenterology. 2020;158(5):1346-1358.e4. https:\/\/doi.org\/10.1053\/j.gastro.2019.12.009.","journal-title":"Gastroenterology."},{"issue":"14","key":"18691_CR11","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473\u201381. https:\/\/doi.org\/10.1001\/jama.2013.279201.","journal-title":"JAMA."},{"issue":"9","key":"18691_CR12","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1245\/s10434-014-3722-6","volume":"21","author":"W Wu","year":"2014","unstructured":"Wu W, He J, Cameron JL, et al. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol. 2014;21(9):2873\u201381. https:\/\/doi.org\/10.1245\/s10434-014-3722-6.","journal-title":"Ann Surg Oncol."},{"issue":"16","key":"18691_CR13","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(16):1763\u201373. https:\/\/doi.org\/10.1200\/JCO.19.02274.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"8","key":"18691_CR14","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1245\/ASO.2006.08.011","volume":"13","author":"GR Varadhachary","year":"2006","unstructured":"Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035\u201346. https:\/\/doi.org\/10.1245\/ASO.2006.08.011.","journal-title":"Ann Surg Oncol."},{"key":"18691_CR15","doi-asserted-by":"publisher","unstructured":"Katz MHG, Pisters PWT, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833-846; discussion 846-848. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2007.12.020","DOI":"10.1016\/j.jamcollsurg.2007.12.020"},{"issue":"1","key":"18691_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13244-020-00861-y","volume":"11","author":"KY Elbanna","year":"2020","unstructured":"Elbanna KY, Jang HJ, Kim TK. Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review. Insights Imaging. 2020;11(1):58. https:\/\/doi.org\/10.1186\/s13244-020-00861-y.","journal-title":"Insights Imaging."},{"issue":"5","key":"18691_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/jso.24361","volume":"114","author":"AN Krepline","year":"2016","unstructured":"Krepline AN, Christians KK, George B, et al. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? J Surg Oncol. 2016;114(5):581\u20136. https:\/\/doi.org\/10.1002\/jso.24361.","journal-title":"J Surg Oncol."},{"key":"18691_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.thromres.2021.08.002","volume":"207","author":"RG Hanna-Sawires","year":"2021","unstructured":"Hanna-Sawires RG, Groen JV, Hamming A, et al. Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer. Thromb Res. 2021;207:134\u20139. https:\/\/doi.org\/10.1016\/j.thromres.2021.08.002.","journal-title":"Thromb Res."},{"issue":"21","key":"18691_CR19","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood.V120.21.3398.3398","volume":"120","author":"JM Ruch","year":"2012","unstructured":"Ruch JM, Bellile E, Hawley AE, Anderson MA, Wakefield TW, Sood SL. Prediction of venous thromboembolism (VTE) in patients with pancreatic cancer using clinical data, biomarkers, and VTE risk models. Blood. 2012;120(21):3398. https:\/\/doi.org\/10.1182\/blood.V120.21.3398.3398.","journal-title":"Blood."},{"issue":"10","key":"18691_CR20","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1182\/bloodadvances.2021006484","volume":"6","author":"TF Overvad","year":"2022","unstructured":"Overvad TF, Ording AG, Nielsen PB, et al. Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. Blood Adv. 2022;6(10):2967\u201376. https:\/\/doi.org\/10.1182\/bloodadvances.2021006484.","journal-title":"Blood Adv."},{"key":"18691_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.thromres.2016.12.013","volume":"150","author":"N van Es","year":"2017","unstructured":"van Es N, Franke VF, Middeldorp S, Wilmink JW, B\u00fcller HR. The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res. 2017;150:30\u20132. https:\/\/doi.org\/10.1016\/j.thromres.2016.12.013.","journal-title":"Thromb Res."},{"issue":"5","key":"18691_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(5):496\u2013520. https:\/\/doi.org\/10.1200\/JCO.19.01461.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"5","key":"18691_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol Off J Eur Soc Med Oncol. 2023;34(5):452\u201367. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.014.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"issue":"9","key":"18691_CR24","doi-asserted-by":"publisher","first-page":"e868","DOI":"10.1200\/JOP.19.00697","volume":"16","author":"CE Holmes","year":"2020","unstructured":"Holmes CE, Ades S, Gilchrist S, et al. Successful model for guideline implementation to prevent cancer-associated thrombosis: venous thromboembolism prevention in the ambulatory cancer clinic. JCO Oncol Pract. 2020;16(9):e868\u201374. https:\/\/doi.org\/10.1200\/JOP.19.00697.","journal-title":"JCO Oncol Pract."},{"issue":"18","key":"18691_CR25","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","volume":"33","author":"U Pelzer","year":"2015","unstructured":"Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(18):2028\u201334. https:\/\/doi.org\/10.1200\/JCO.2014.55.1481.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"9","key":"18691_CR26","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","volume":"48","author":"A Maraveyas","year":"2012","unstructured":"Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer Oxf Engl 1990. 2012;48(9):1283\u201392. https:\/\/doi.org\/10.1016\/j.ejca.2011.10.017.","journal-title":"Eur J Cancer Oxf Engl 1990."},{"issue":"8","key":"18691_CR27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1814630.","journal-title":"N Engl J Med."},{"issue":"8","key":"18691_CR28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1814468.","journal-title":"N Engl J Med."},{"issue":"5","key":"18691_CR29","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1245\/s10434-018-07148-z","volume":"26","author":"BA Boone","year":"2019","unstructured":"Boone BA, Zenati MS, Rieser C, et al. Risk of venous thromboembolism for patients with pancreatic ductal adenocarcinoma undergoing preoperative chemotherapy followed by surgical resection. Ann Surg Oncol. 2019;26(5):1503\u201311. https:\/\/doi.org\/10.1245\/s10434-018-07148-z.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18691-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18691-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18691-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:39:43Z","timestamp":1770899983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18691-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["18691"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18691-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Robin Wright is supported by the NIH T32 Fellowship in the Department of Surgical Oncology at MD Anderson Cancer Center. This work was also supported by the NIH\/NCI under award no. P30CA016672.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}